Welcome to our dedicated page for Organogenesis Hldgs SEC filings (Ticker: ORGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Organogenesis Holdings Inc.'s SEC filings document a regenerative medicine issuer with Class A common stock listed on the Nasdaq Capital Market. The filings cover operating and financial results for Advanced Wound Care and Surgical & Sports Medicine products, including furnished 8-K earnings releases that separate product revenue by market category.
The company's regulatory record also includes proxy materials for annual meeting matters, director elections, advisory voting items, board governance and compensation disclosures. Other filings address Regulation FD and material-event updates for ReNu clinical and regulatory matters, capital-structure details involving Class A common stock and Series A Convertible Preferred Stock voting mechanics, and risk and governance topics tied to its product portfolio.
Organogenesis Holdings Inc. executive Lori Freedman, Chief Administrative and Legal Officer, reported multiple equity awards. She received a stock option for 115,812 shares at $0 per share, vesting in equal annual installments over four years beginning February 15, 2026. She was also granted 203,125 restricted stock units under the 2018 Equity Incentive Plan, each convertible into one share of Class A common stock, vesting annually over four years from the same date. In addition, 42,780 shares of Class A common stock were issued upon vesting and settlement of a 2025 performance share award. A separate disposition of 14,267 shares at $3.84 per share was reported to cover tax obligations by delivering shares, leaving her with 1,023,355 Class A shares directly owned after these transactions.
Organogenesis Holdings Inc. vice president Robert Cavorsi reported multiple equity awards and a related tax share disposition. He received stock options for 53,452 shares at an exercise price of $0.00 and now holds 53,452 derivative securities. He was also granted 93,750 shares of Class A common stock and a further 16,290 shares, bringing his direct Class A holdings to 276,115 shares after all transactions.
The awards include restricted stock units that vest in equal annual installments over four years beginning February 15, 2026, and options that become exercisable on the same schedule. Some shares were issued from a 2025 performance share award tied to performance milestones. A total of 5,432 shares were withheld and disposed at $3.84 per share to cover tax obligations.
Organogenesis Holdings Inc. reported that Chief Financial Officer Francisco David received equity awards and had shares withheld for taxes. He was granted a stock option for 111,358 shares with no exercise cost shown here, vesting in equal annual installments over four years beginning February 15, 2026. He also received 195,312 restricted stock units, each convertible into one share of Class A common stock as they vest annually over four years starting on the same date. In addition, 43,602 shares of Class A common stock were issued upon vesting of a 2025 performance share award tied to performance milestones, and 14,541 shares were disposed of at $3.84 per share to cover tax obligations. Following these transactions, he directly owned 731,020 Class A shares.
Organogenesis Holdings Inc. reported that Chief Commercial Officer Brian Grow received new equity awards and had shares withheld for taxes. He was granted a stock option for 133,630 shares with no exercise price shown here; the option vests in equal annual installments over four years beginning February 15, 2026.
Grow also acquired 234,375 shares and 48,330 shares of Class A common stock as equity awards, tied to restricted stock units and a performance share award that vest over time based on service and performance. In connection with the vesting of the performance award, 11,768 shares were disposed of at $3.84 per share to satisfy tax withholding obligations, leaving him with 899,355 shares of Class A common stock held directly.
Organogenesis Holdings Inc. Chief Operating Officer Patrick Bilbo reported new equity awards and related tax withholding transactions. He received a stock option covering 120,267 shares of Class A common stock and was granted or issued a total of 259,549 Class A shares through stock awards on February 18, 2026.
The equity awards include restricted stock units that vest in equal annual installments over four years beginning February 15, 2026, as well as shares issued from a 2025 performance share award based on achievement of performance milestones. In a separate transaction, 16,212 shares were disposed of at $3.84 per share to cover tax obligations tied to these awards.
Organogenesis Holdings Inc. reported that President and CEO Gary S. Gillheeney received equity awards and related share settlements. He was granted 890,625 restricted stock units that vest in equal annual installments over four years beginning February 15, 2026. He also received 186,968 shares of Class A common stock upon vesting and settlement of a 2025 performance share award tied to performance milestones. To cover tax obligations, 90,398 shares were disposed of at $3.84 per share. In addition, he was granted stock options for 507,795 shares, which become exercisable in equal annual installments over four years beginning February 15, 2026, bringing his directly held Class A shares to 4,231,112 and option holdings to 507,795.
Organogenesis Holdings Inc. director Michael Joseph Driscoll received an equity grant in the form of restricted stock units (RSUs) covering 48,828 shares of Class A common stock. The award was granted at no cash cost per share and represents a compensation-related acquisition, not an open-market purchase.
Each RSU converts into one share of Class A common stock upon vesting. The RSUs vest in full on February 15, 2027, meaning Driscoll will receive the underlying shares only if the vesting conditions are satisfied. Following this grant, his directly held Class A share balance reported in this filing is 215,707 shares.
Giacomin Jon L reported acquisition or exercise transactions in this Form 4 filing.
Organogenesis Holdings Inc. director Jon L. Giacomin reported receiving an equity grant in the form of restricted stock units (RSUs). The award covers 48,828 RSUs, each representing one share of Class A common stock upon vesting. These RSUs vest in full on February 15, 2027, aligning his compensation with long‑term shareholder value. Following this grant, Giacomin directly owns 241,026 shares of Organogenesis Class A common stock.
Organogenesis Holdings Inc. director Arthur S. Leibowitz reported an equity award of Class A common stock. He acquired 48,828 shares through a grant of restricted stock units (RSUs) at no cash cost, increasing his directly held stake to 286,014 shares after the transaction.
The RSUs were granted under the Organogenesis 2018 Equity Incentive Plan. Each RSU converts into one share of Class A common stock upon vesting, and the entire award is scheduled to vest in full on February 15, 2027, aligning director compensation with the company’s long-term performance.
Organogenesis Holdings Inc. vice president Antonio S. Montecalvo reported multiple equity compensation awards. On February 18, 2026, he received a stock option for 23,162 shares at an exercise price of $0.00 and restricted stock units for 40,625 shares and 11,218 shares of Class A common stock.
The RSUs were granted under the 2018 Equity Incentive Plan and vest in equal annual installments over four years beginning on February 15, 2026. The option also becomes exercisable in equal annual installments over four years beginning on the same date.
In connection with the vesting and settlement of a 2025 performance share award based on achievement of performance milestones, 3,741 Class A shares were disposed of at $3.84 per share to cover tax withholding, leaving Montecalvo with 226,163 Class A shares held directly.